GTC Biotherapeutics (fka GTCB)

[croumagnon]

"I think it will be much less than that—probably less than 20%. To be clear: I am talking about a PR that contains only the top-line data from the US HD trial and does not have a simultaneous announcement about a partnership or another matter of economic consequence."

You seem to be in the underpromise and overdeliver camp lately... LOL..

20% from where we are will only take us as far as 1.12, which is nothing as we were there not too long ago! On the other hand, bad top line data could crash the stock real hard so, according to your guidance, GTCB is not a good investment currently unless a major partnership announcement is imminent...

If you Dew, the main champion of GTCB, have such low expectations from this stock in the near-term, then no wonder people are selling and using GTCB as a tax-loss stock...